Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings
详细信息 查看全文
- 作者：Nobuyuki Tanaka ; M.D. ; Ph.D.a ; e ; 1 ; urotanaka@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Ryuichi Mizuno ; M.D. ; Ph.D.a ; 1 ; mizunor@z7.keio.jp" class="auth_mail" title="E-mail the corresponding author ; Suguru Shirotake ; M.D. ; Ph.D.b ; Keiichi Ito ; M.D. ; Ph.D.c ; Yota Yasumizu ; M.D.b ; Ayako Masunaga ; M.D.c ; Yujiro Ito ; M.D.d ; Yasumasa Miyazaki ; M.D.a ; Masayuki Hagiwara ; M.D.g ; Kent Kanao ; M.D. ; Ph.D.i ; Shuji Mikami ; M.D. ; Ph.D.h ; Ken Nakagawa ; M.D. ; Ph.D.g ; Tetsuo Momma ; M.D. ; Ph.D.f ; Takeshi Masuda ; M.D.e ; Tomohiko Asano ; M.D. ; Ph.D.c ; Masafumi Oyama ; M.D. ; Ph.D.b ; Mototsugu Oya ; M.D. ; Ph.D.a
- 关键词：Renal cell carcinoma ; Metastasis ; Targeted therapy ; Outcome ; Prognosis ; IMDC ; Reclassification
- 刊名：Urologic Oncology: Seminars and Original Investigations
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：34
- 期：7
- 页码：293.e17-293.e25
- 全文大小：367 K
文摘
- •
Reclassification of the IMDC model after targeted therapy may be prognostic in mRCC.
- •
Up to 30% of cohorts are reclassified into different risks in the 1st-line setting.
- •
Up to 20% of cohorts are reclassified into different risks in the 2nd-line setting.
- •
Overall survivals are newly stratified by using the IMDC model reclassification.